Ezutromid Shows Potential to Treat DMD

Ezutromid

Summit Therapeutics plc has announced encouraging interim results from its phase 2 PhaseOut DMD clinical trial that suggest the MDA research grant-funded experimental treatment ezutromid (formerly SMT C1100) potentially may be effective as a treatment for DMD.

Read More